Goldline Pharmaceutical SME IPO Subscription Status
Goldline Pharmaceutical SME IPO closed on 14 May 2026 with an overall subscription of 840.81x based on shares applied. QIB demand came in at 180.22x, NII at 1,662.39x, and retail at 881.15x.
Allotment will be finalised on 15 May 2026. The stock is scheduled to list on NSE and BSE on 19 May 2026.
Issue Price
Rs 43.00
GMP Today
Rs 15.00 (+34.88%)
Overall Subscription
840.81x
Issue Size
₹11.61 Cr
Allotment Date
15 May 2026
Listing Date
19 May 2026
Goldline Pharmaceutical SME IPO Subscription by Amount
Category-wise subscription based on amount applied at issue price Rs 43.00
| Category | Amount Offered | Amount Applied | Subscription |
|---|---|---|---|
| QIB | Rs 2.32 Cr | Rs 418.46 Cr | 180.22x |
| FII | - | Rs 109.38 Cr | - |
| DFI | - | Rs 3.87 L | - |
| Mutual Funds | - | - | - |
| Other | - | Rs 309.05 Cr | - |
| NII | Rs 1.68 Cr | Rs 2,787.83 Cr | 1,662.39x |
| bNII (above Rs 10L) | Rs 1.12 Cr | Rs 2,231.16 Cr | 1,995.67x |
| Corporate | - | Rs 19.26 Cr | - |
| Individual | - | Rs 2,187.30 Cr | - |
| Other | - | Rs 24.60 Cr | - |
| sNII (Rs 2L to Rs 10L) | Rs 55.90 L | Rs 556.67 Cr | 995.84x |
| Corporate | - | Rs 2.22 Cr | - |
| Individual | - | Rs 549.41 Cr | - |
| Other | - | Rs 5.04 Cr | - |
| IND | Rs 3.87 Cr | Rs 3,410.06 Cr | 881.15x |
| Fixed price | - | Rs 3,410.06 Cr | - |
| Total | Rs 7.87 Cr | Rs 6,616.36 Cr | 840.81x |
Goldline Pharmaceutical SME IPO Subscription by Applications
Category-wise subscription based on applications received
| Category | Applications Offered | Applications Received | Subscription |
|---|---|---|---|
| QIB | 180 | 85 | 0.47x |
| FII | - | 23 | - |
| DFI | - | 1 | - |
| Mutual Funds | - | - | - |
| Other | - | 61 | - |
| NII | 43 | 33,760 | 785.12x |
| bNII (above Rs 10L) | 29 | 20,429 | 704.45x |
| Corporate | - | 172 | - |
| Individual | - | 20,021 | - |
| Other | - | 236 | - |
| sNII (Rs 2L to Rs 10L) | 14 | 13,331 | 952.21x |
| Corporate | - | 54 | - |
| Individual | - | 13,153 | - |
| Other | - | 124 | - |
| IND | 150 | 1,32,173 | 881.15x |
| Fixed price | - | 1,32,173 | - |
| Total | 373 | 1,66,018 | 445.09x |
What Do These Subscription Numbers Mean?
A subscription of 840.81x by shares means the IPO received bids for 841 times the shares reserved. Allotment odds depend on application count in each category, not share volume.
Here is what each category number tells you:
QIB at 180.22x by shares: This is the strongest signal on the page. QIBs are institutional investors, mutual funds, foreign institutions, and banks. When they subscribe at 180.22x, it reflects serious institutional conviction.
NII at 785.12x by applications: NII includes high net worth individuals applying above Rs 2 lakh. Proportional allotment uses application subscription. bNII came in at 704.45x and sNII at 952.21x by applications. Share subscription was 1,662.39x. Allotment uses application count, not share volume.
At 881.15x subscription by applications, approximately 1 in 881 retail applicants can expect an allotment (~1% per application). Retail allotment is done by lottery when oversubscribed.
Goldline Pharmaceutical SME IPO Allotment Chances
Allotment odds below use application subscription (number of bids received), not share or amount subscribed.
Retail (IND)
- •Application subscription: 881.15x.
- •Allotment odds: about 1 in 881 (~1% chance per application).
- •Method: Lottery. If allotted, you receive at least one lot.
- •One application per PAN. Multiple eligible accounts in a household can improve overall family odds, not individual odds.
SHNI (Rs 2 lakh to Rs 10 lakh)
- •Application subscription: 952.21x.
- •Allotment odds: about 1 in 952 for a minimum-lot application (~1% of the applied lot on average).
- •Method: Proportional. Shares allotted are based on your bid size, not a lottery.
- •Share subscription was 995.84x. Allotment uses application count, not share volume.
BHNI (above Rs 10 lakh)
- •Application subscription: 704.45x.
- •Allotment odds: about 1 in 704 for a minimum-lot application (~1% of the applied lot on average).
- •Method: Proportional. Shares allotted are based on your bid size, not a lottery.
- •Share subscription was 1,995.67x. Allotment uses application count, not share volume.
Check the Goldline Pharmaceutical SME IPO Allotment Status page from 15 May 2026 for your allotment result.
Goldline Pharmaceutical SME IPO GMP After Subscription
GMP for Goldline Pharmaceutical SME stands at Rs 15.00 today, giving an estimated listing price of Rs 58.00 per share.
A subscription of 840.81x combined with a GMP of 34.88% is a strong combination heading into listing. QIB demand above 50x in particular tends to support listing sentiment, as institutional investors are seen as informed buyers.
Track live GMP on the Goldline Pharmaceutical SME IPO GMP Today page or the IPOwiz Live IPO GMP Tracker.
Goldline Pharmaceutical SME IPO Day-wise Subscription
| Day | QIB | NII | Retail | Overall |
|---|---|---|---|---|
| Day 1 - 12 May 2026 | 1.31x | 24.46x | 34.07x | 22.35x |
| Day 2 - 13 May 2026 | 1.31x | 146.12x | 139.51x | 100.14x |
| Day 3 - 14 May 2026 | 180.22x | 1,662.04x | 881.15x | 840.74x |
Goldline Pharmaceutical SME IPO Key Dates
| Event | Date |
|---|---|
| IPO Open Date | 12 May 2026 |
| IPO Close Date | 14 May 2026 |
| Allotment Date | 15 May 2026 |
| Refund Initiation | 16 May 2026 |
| Share Credit to Demat | 16 May 2026 |
| Listing Date | 19 May 2026 |
| Minimum Investment | Rs 2,58,000.00 |
| Lot Size | 3000 shares |
About Goldline Pharmaceutical SME
Goldline Pharmaceutical Limited, incorporated in 2021, is a pharmaceutical marketing company that operates under an asset-light business model. The company markets a wide range of pharmaceutical formulations under its proprietary brand 'Goldline', across five specialized divisions: Pharma (General), Cardinal (Specialty), Aayushman (Pediatric), InLife (Critical Care), and Wellness (Supportive Care). Instead of in-house manufacturing, Goldline partners with 15 third-party manufacturers and utilizes a network of 7 distributors to supply products to retailers and hospitals across Maharashtra, Tamil Nadu, Rajasthan, and other states.
Understanding Subscription Categories
QIB - Qualified Institutional Buyers
Includes foreign institutional investors, domestic financial institutions, mutual funds, and other qualified institutions. QIB demand is considered the most reliable indicator of institutional confidence in an IPO.
NII - Non-Institutional Investors
High net worth individuals applying above Rs 2 lakh. Divided into bNII (above Rs 10 lakh) and sNII (Rs 2 lakh to Rs 10 lakh). NII allotment is proportional.
IND - Individual Investors
Investors applying up to Rs 2 lakh per PAN. Allotment is by lottery when oversubscribed. Minimum one lot per successful applicant.
Goldline Pharmaceutical SME IPO GMP Today
Live GMP, listing price estimate, and listing gain
Goldline Pharmaceutical SME IPO Allotment Status
Check allotment result on allotment date
Goldline Pharmaceutical SME IPO Details
Financials, peers, strengths, and review
All IPO Subscription Status
Subscription for all active IPOs
Goldline Pharmaceutical SME IPO Subscription FAQs
What is Goldline Pharmaceutical SME IPO subscription status today?
Goldline Pharmaceutical SME IPO subscription closed on 14 May 2026 with overall subscription of 840.81x (by shares) as of 9 July 2026, 4:01 PM IST. QIB 180.22x, NII 785.12x, IND 881.15x.
What is the overall subscription of Goldline Pharmaceutical SME IPO?
Goldline Pharmaceutical SME IPO is subscribed 840.81x overall by shares at close on 14 May 2026. QIB 180.22x, NII 785.12x, and IND 881.15x.
What is Goldline Pharmaceutical SME IPO QIB subscription?
Goldline Pharmaceutical SME IPO QIB (Qualified Institutional Buyers) subscription is 180.22x by shares. QIB includes mutual funds, FIIs, banks, and other institutions.
What is Goldline Pharmaceutical SME IPO IND subscription?
Goldline Pharmaceutical SME IPO IND subscription is 881.15x by applications. Minimum retail bid is up to Rs 2 lakh per PAN.
What is Goldline Pharmaceutical SME IPO NII subscription?
Goldline Pharmaceutical SME IPO NII (Non-Institutional Investors) subscription is 785.12x by applications. NII covers bids above Rs 2 lakh.
What are allotment chances in Goldline Pharmaceutical SME IPO for retail?
At 881.15x subscription by applications, approximately 1 in 881 retail applicants can expect an allotment (~1% per application). Allotment is done by lottery.
When is Goldline Pharmaceutical SME IPO allotment date?
Goldline Pharmaceutical SME IPO allotment date is 15 May 2026. Check Goldline Pharmaceutical SME IPO Allotment Status on IPOwiz from that day using your PAN.
When does Goldline Pharmaceutical SME IPO subscription close?
Goldline Pharmaceutical SME IPO subscription closed on 14 May 2026. No new applications are accepted after the close.
What is Goldline Pharmaceutical SME IPO GMP today?
Goldline Pharmaceutical SME IPO GMP is ₹15 today (+34.88% over issue price ₹43). See live GMP on the Goldline Pharmaceutical SME IPO GMP Today page.
What is Goldline Pharmaceutical SME IPO issue price and lot size?
Goldline Pharmaceutical SME IPO issue price is ₹43 per share. Lot size is 3000 shares. Minimum investment is ₹2,58,000 per lot (minimum 2 lots for SME). Issue size: ₹11.61 Cr.
When is Goldline Pharmaceutical SME IPO listing date?
Goldline Pharmaceutical SME IPO listing date is 19 May 2026 on NSE and BSE. Allotment is on 15 May 2026.
How does subscription affect Goldline Pharmaceutical SME IPO allotment?
Allotment odds in Goldline Pharmaceutical SME IPO depend on application subscription in each category, not share volume. Retail uses lottery when oversubscribed. NII proportional allotment at 785.12x by applications means roughly 1 in 785 for minimum-lot bids; bNII at 704.45x (~1 in 704). At 840.81x overall, competition is very high.
For allotment results from 15 May 2026, visit the Goldline Pharmaceutical SME IPO Allotment Status page. For listing day updates on 19 May 2026, download the IPOwiz App.
Reviewed by Dinesh Agrawal
15+ years in Indian capital markets and IPO research. Subscription data verified before publish.